Search

Patients can play active role in shaping drug development and treatment goals, but they need intelligible information to do so

The Scientific Advice Mechanism team has delivered its first report, concluding a new way of assessing vehicle exhaust gases will reduce discrepancies between the lab and the road

What Trump’s election could mean for science and technology – if we keep our heads

The joint effort of Aalto, University of Helsinki and HUS may help Parkinson's patients and people with memory disorders.

A UCL-led consortium has been awarded £4m to establish a new national High Performance Computing (HPC) facility for the Materials and Molecular Modelling community.

Researchers at ETH Zurich have developed a new cell culture method, which may very well enable to forgo certain tests on animals in the future. The scientists were awarded an international prize for more humane treatment of laboratory animals.

Preparations for future €1B research project include several UK figures

Trump’s lead in the social media stakes contributed to the election victory, says the tech leaders meeting in Lisbon

Uncertainty over the future home of the EU’s drug regulator is impacting recruitment and staff motivation, director tells MEPs

Europe confronts implications of remarkable upset in US election. ‘He has no idea about technology,’ says MEP

A very comprehensive 2011 report that contains a basic introduction to PROMs and their potential to improve healthcare services, as well as recommendations for methods of data collection and interpretation and understanding outcomes.

As part of its regular review of health systems in the developed countries, the Organisation for Economic Cooperation and Development has been incorporating more statistics on what patients think of their treatments. This site includes a selection of results, and recommendations.

A 2016 policy paper that showcases the importance of measuring outcomes for greater transparency in and oversight of the performance of European healthcare systems.

European Commission wants new public-private fund of funds to bolster VC markets and funnel money to start-ups

One of the problems of analysing patient outcomes is discriminating clearly between different diseases and variants.That’s the case for type 1 and 2 diabetes – different syndromes, but not always analysed separately in the health data.

This provides a new look at the way patients are asked about the effect of the prescription drugs they take. While questionnaires about effectiveness, side-effects or other concerns are common, how standardised are they, or can they be?

Cancer is a horrible diagnosis for anybody – but it can seem especially tough for teenagers and young adults. How do you ask them about it? What can you learn from their answers, to treat others?

Kay Swinburne, a British member of the European Parliament envisions an intergovernmental future for the London-based European Medicines Agency. “Can’t the EMA become a much broader agency that serves not just the EU but the whole of Europe?” Swinburne asked at a Science|Business meeting last month.

The head of the health division at the OECD, Francesca Colombo, says members are making poor use of health data. She is calling for a broader collection of personal health information, to reflect the outcomes that matter to patients